Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3701
Rayonier Advanced Materials
RYAM
$482M
| $592K | ﹤0.01% |
100,484
+4,348
| +5% | +$28.3K |
2014 Q3
45 quarters
|
|
|
BBU
3702
DELISTED
Brookfield Business Partners
BBU
| $590K | ﹤0.01% |
16,751
+14,817
| +766% | +$508K |
2025 Q1
3 quarters
|
|
3703
Vaalco Energy
EGY
$603M
| $588K | ﹤0.01% |
161,486
+15,625
| +11% | +$57.8K |
2022 Q2
14 quarters
|
|
3704
Spok Holdings
SPOK
$228M
| $587K | ﹤0.01% |
44,520
+2,313
| +5% | +$32.8K |
2013 Q2
50 quarters
|
|
3705
Vanguard Dividend Appreciation ETF
VIG
$110B
| $587K | ﹤0.01% |
2,670
-4,470
| -63% | -$977K |
2023 Q4
8 quarters
|
|
|
STRZ
3706
Starz Entertainment Corp
STRZ
$398M
| $586K | ﹤0.01% |
50,106
+14,006
| +39% | +$160K |
2025 Q2
2 quarters
|
|
|
AII
3707
American Integrity Insurance
AII
$511M
| $586K | ﹤0.01% |
28,121
+16,773
| +148% | +$373K |
2025 Q3
1 quarter
|
|
|
FPI
3708
Farmland Partners
FPI
$490M
| $586K | ﹤0.01% |
60,441
+2,051
| +4% | +$20.6K |
2017 Q1
35 quarters
|
|
3709
Chunghwa Telecom
CHT
$35.8B
| $585K | ﹤0.01% |
+14,036
| New | +$593K |
2025 Q4
0 quarters
|
|
3710
West Bancorporation
WTBA
$513M
| $585K | ﹤0.01% |
26,341
+5,104
| +24% | +$110K |
2016 Q3
37 quarters
|
|
3711
First Western Financial
MYFW
$294M
| $584K | ﹤0.01% |
21,788
+1,244
| +6% | +$29.7K |
2020 Q2
22 quarters
|
|
3712
Ribbon Communications
RBBN
$317M
| $583K | ﹤0.01% |
202,461
+47,690
| +31% | +$154K |
2013 Q2
50 quarters
|
|
3713
Intrepid Potash
IPI
$441M
| $583K | ﹤0.01% |
21,012
+5,449
| +35% | +$146K |
2022 Q1
15 quarters
|
|
3714
Lineage Cell Therapeutics
LCTX
$235M
| $582K | ﹤0.01% |
348,510
+348,509
| +34,850,900% | +$603K |
2022 Q3
13 quarters
|
|
3715
Brookfield Renewable
BEP
$8.51B
| $580K | ﹤0.01% |
21,499
+5,122
| +31% | +$146K |
2020 Q3
21 quarters
|
|
3716
Bridgewater Bancshares
BWB
$577M
| $579K | ﹤0.01% |
33,013
+3,137
| +11% | +$54.4K |
2018 Q2
30 quarters
|
|
3717
CALL
Zoom
ZM
$27.1B
| $578K | ﹤0.01% |
6,700
| – | – |
2025 Q3
1 quarter
|
|
3718
Reynolds Consumer Products
REYN
$4.7B
| $575K | ﹤0.01% |
25,107
+23,149
| +1,182% | +$558K |
2022 Q1
15 quarters
|
|
|
BRCB
3719
Black Rock Coffee Bar Inc
BRCB
$155M
| $573K | ﹤0.01% |
25,767
+15,643
| +155% | +$363K |
2025 Q3
1 quarter
|
|
3720
Fidelity D&D Bancorp
FDBC
$321M
| $572K | ﹤0.01% |
13,141
-10
| -0.1% | -$443 |
2018 Q2
30 quarters
|
|
3721
JFrog
FROG
$11.8B
| $571K | ﹤0.01% |
9,145
+8,989
| +5,762% | +$511K |
2023 Q1
11 quarters
|
|
|
CVGW
3722
DELISTED
Calavo Growers
CVGW
| $571K | ﹤0.01% |
26,248
+2,288
| +10% | +$50.7K |
2016 Q1
39 quarters
|
|
|
NEXN
3723
Nexxen International
NEXN
$502M
| $571K | ﹤0.01% |
87,288
+288
| +0.3% | +$2.14K |
2022 Q2
14 quarters
|
|
3724
ADC Therapeutics
ADCT
$144M
| $570K | ﹤0.01% |
161,386
+30,926
| +24% | +$125K |
2024 Q2
6 quarters
|
|
3725
iShares Russell 1000 Value ETF
IWD
$81.4B
| $568K | ﹤0.01% |
+2,700
| New | +$558K |
2025 Q4
0 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.